NCT06495177 European Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease (EUROASPIRE VI)
| NCT ID | NCT06495177 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Society of Cardiology |
| Condition | Coronary Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 8,000 participants |
| Start Date | 2024-06-07 |
| Primary Completion | 2025-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 8,000 participants in total. It began in 2024-06-07 with a primary completion date of 2025-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to provide a unique European picture of preventive action by cardiologists, other specialists and primary care physicians looking after patients with coronary heart disease (CHD), individuals at high cardiovascular disease risk and all those with hypertension, dyslipidaemia (including familial hypercholesterolaemia), diabetes and dysglycaemia and chronic kidney disease (CKD) and determine whether the European guidelines on cardiovascular disease prevention, hypertension, lipids, diabetes and chronic kidney disease are being followed.
Eligibility Criteria
Inclusion Criteria: * Patients having signed an informed Consent * Patients aged from 18 years old at the time of identification * At least six and at most 24 months elapsed between the index event (the recruiting diagnostic or treatment criteria below) and the date of interview * Patients meeting the recruiting diagnostic or treatment criteria: * Coronary patients: Acute coronary events (acute coronary syndrome {STEMI or NSTEMI}, unstable angina) or an emergency or elective revascularisation for coronary artery disease (CABG, PCI) * High cardiovascular disease (CVD) risk patients: patients free of CVD, who have been prescribed one or more of the following treatments: blood pressure and/or lipid-lowering and/or glucose lowering (diet and/or hypoglycaemic agents and/or insulin) Exclusion Criteria: * Patients living outside defined geographical areas * Patients admitted to hospital from outside the geographical area or under the care of cardiologists in hospitals that do not participate in EUROASPIRE VI
Contact & Investigator
Pr David A Wood, MB ChB MSc
STUDY CHAIR
National Institute for Prevention and Cardiovascular Health
Frequently Asked Questions
Who can join the NCT06495177 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06495177 currently recruiting?
Yes, NCT06495177 is actively recruiting participants. Contact the research team at registries@escardio.org for enrollment information.
Where is the NCT06495177 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT06495177 clinical trial?
NCT06495177 is sponsored by European Society of Cardiology. The principal investigator is Pr David A Wood, MB ChB MSc at National Institute for Prevention and Cardiovascular Health. The trial plans to enroll 8,000 participants.